Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Shire Human Genetic Therapies, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
New studies indicate that in about 1 - 2 percent of the younger stroke patients the cause could have been an undiagnosed genetic disease, the so called Fabry disease. In this case certain fat molecules are not digested and broken down by the body - but remain in the cells. These fat molecules build up to dangerous levels, which start to damage the body, because they accumulate e.g. in the walls of the blood vessels. This accumulation in the blood vessels of the whole body may cause life-threatening malfunctions in the brain, inducing a stroke.
The purpose of this study is to investigate the stroke rehabilitation of Fabry patients during different therapeutic standard approaches for stroke and for Fabry disease (if any). During this study, stroke patients with Fabry disease will be monitored in greater detail to determine whether the differences in treatment are significant for patient recovery and on what they depend.
In a group of young stroke patients with diagnosed Fabry disease the stroke rehabilitation will be investigated during different prophylactic therapeutic approaches. In this study the investigator will not be given any instructions on stroke and Fabry therapy.
All patients with any etiology of stroke and a diagnosed Fabry disease submitted to the stroke unit of the participating centres which commit to work with the EUSI (European Stroke Initiative) recommendations for stroke management and diagnosis will be included into the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Observation | Adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology and the genetic diagnosis (a-galactosidase defect) of Fabry disease |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Determination of the relapse rate of acute cerebrovascular events with clinical relevance in patients with different prophylactic approaches | 54 months study duration |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life measured with the SF-36 | 54 months study duration | |
| Number of acute CVEs without clinical significance but with obvious signs in MRI diagnosis | 54 months study duration | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Adult patients (18 - 55 years of age) with an acute cerebrovascular event (CVE) of any etiology defined as patients having an ischemic stroke or transient ischemic attack and genetic diagnosis (a-galactosidase defect) of Fabry disease.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arndt Rolfs, Prof., MD | University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universitätsklinikum für Neurologie | Graz | A-8036 | Austria | |||
| Department of Neurology, University Hospital Sestre Milosrdnice |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 16298216 | Background | Rolfs A, Bottcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, Lohr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005 Nov 19;366(9499):1794-6. doi: 10.1016/S0140-6736(05)67635-0. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
EDTA-blood and urine sample for central laboratory analysis of agalsidase antibodies and Gb3 for safety issues.
There will be a proteomic analysis in blood to check whether there will be the possibility to characterize a biomarker for Fabry disease.
| Beck Depression Inventory II (BDI II) |
| 54 months study duration |
| Brief Pain Inventory (BPI) | 54 months study duration |
| Rostocker Kopfschmerzfragen-Komplex (RoKoKo) (only in Austria and Germany) | 54 months study period |
| Habi test (only in Austrian and German centers) | 54 months study duration |
| Trail Making Test (TMT) | 54 months study duration |
| Functional neurological deficits measured by the Mini Mental State Examination (MMSE) | 54 months study duration |
| Zagreb |
| 10000 |
| Croatia |
| Hopital Neurologique de Lyon, Service d'urgences Neurovasculaires | Lyon | F-69003 | France |
| Department of Neurology, S. Khechinashvili University clinic of Tbilisi state medical university | Tbilisi | 0179 | Georgia |
| Department of Neurology, Klinikum Hohe Warte | Bayreuth | 95445 | Germany |
| Charite Campus Benjamin Franklin, Dept. of Neurology | Berlin | D-12200 | Germany |
| Department of Neurology, Allgemeines Krankenhaus Celle | Celle | 29223 | Germany |
| Department of Neurology, Klinikum Chemnitz gGmbH | Chemnitz | 09131 | Germany |
| Department of Neurology, Universitaetsklinikum Carl Gustav Carus | Dresden | 01307 | Germany |
| Heinrich-Heine-University Duesseldorf, Dept. of Neurology | Düsseldorf | D-40225 | Germany |
| University of Giessen-Marburg Dept. of Neurology | Giessen | D-35385 | Germany |
| Department of Neurology, Universitaetsklinikum Hamburg-Eppendorf | Hamburg | 20246 | Germany |
| Department of Neurology, Universitaetsklinikum Jena | Jena | 07740 | Germany |
| Department of Neurology, Universitaetsklinikum Leipzig | Leipzig | 04103 | Germany |
| Dept. of Neurology, Ökumenisches Hainich Klinikum gGmbH | Mühlhausen | 99974 | Germany |
| Ludwig-Maximilians-University of Munich, Klinikum München-Großhadern, Dept. of Neurology | München | D-81377 | Germany |
| Department of Neurology, University Tuebingen | Tübingen | 72076 | Germany |
| University of Ulm, Department of Neurology | Ulm | D-89081 | Germany |
| Institute of Psychiatry and Neurology, Dept. of Neurology | Warsaw | 02-957 | Poland |
| Centro Hospitalar de Lisboa Central, Servico de Neurologia | Lisbon | 1150-199 | Portugal |
| ID | Term |
|---|---|
| D000795 | Fabry Disease |
| D020521 | Stroke |
| ID | Term |
|---|---|
| D013106 | Sphingolipidoses |
| D020140 | Lysosomal Storage Diseases, Nervous System |
| D020739 | Brain Diseases, Metabolic, Inborn |
| D001928 | Brain Diseases, Metabolic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D059345 | Cerebral Small Vessel Diseases |
| D002561 | Cerebrovascular Disorders |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D040181 | Genetic Diseases, X-Linked |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008661 | Metabolism, Inborn Errors |
| D008064 | Lipidoses |
| D008052 | Lipid Metabolism, Inborn Errors |
| D016464 | Lysosomal Storage Diseases |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D052439 | Lipid Metabolism Disorders |
Not provided
Not provided